# Tempest Therapeutics, Inc.: overview TPST · Nasdaq · CIK 1544227 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/tpst.md) · [Financials](/companies/tpst/financials.md) · [Filings](/companies/tpst/filings.md) · [Insiders](/companies/tpst/insiders.md) Latest reported revenue: [$55.0k](/filings/0001544227-18-000009.md) for Q3 FY2018, three months to 2018-09-30, from the 10-Q filed Nov 9, 2018 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001544227-18-000009). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(5.32)](/filings/0001193125-25-265946.md) | not reported | [(3.16)](/filings/0001193125-26-224289.md) | [(2.07)](/filings/0001193125-26-349381.md) | [(0.79)](/filings/0001193125-25-265946.md) | not reported | [(2.53)](/filings/0001193125-26-224289.md) | [(0.34)](/filings/0001193125-26-349381.md) | | Free cash flow | $m | [(10.2) d](/filings/0001193125-25-265946.md) | [(10.2) d](/filings/0001193125-26-130490.md) | [(8.0)](/filings/0001193125-26-224289.md) | [(8.4) d](/filings/0001193125-26-349381.md) | [(6.8) d](/filings/0001193125-25-265946.md) | [(3.6) d](/filings/0001193125-26-130490.md) | [(7.6)](/filings/0001193125-26-224289.md) | [(2.8) d](/filings/0001193125-26-349381.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(7.47)](/filings/0000950170-23-009237.md) | [(3.09)](/filings/0000950170-24-033555.md) | [(1.91)](/filings/0000950170-25-046144.md) | [(19.50)](/filings/0001193125-26-130490.md) | [(6.33)](/filings/0001193125-26-130490.md) | | Free cash flow | $m | [(26.1)](/filings/0000950170-23-009237.md) | [(31.6)](/filings/0000950170-24-033555.md) | [(27.5)](/filings/0000950170-25-046144.md) | [(33.5)](/filings/0001193125-26-130490.md) | [(26.8)](/filings/0001193125-26-130490.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/tpst/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [SABBY MANAGEMENT, LLC](/funds/1535610.md) | 2026-06-30 | $567.5k | 511,286 | | Added +493,430 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $259.6k | 233,888 | | Unchanged | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $96.2k | 86,625 | | Reduced −365 | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $76.5k | 68,908 | | Unchanged | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $43.4k | 39,068 | | Unchanged | | [Squarepoint Ops LLC](/funds/1642575.md) | 2026-06-30 | $34.3k | 30,900 | | New +30,900 | | [NORTHERN TRUST CORP](/funds/73124.md) | 2026-06-30 | $22.4k | 20,136 | | Added +6,083 | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $22.0k | 19,820 | | New +19,820 | | [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $6.3k | 5,636 | | Added +1,103 | | [Tower Research Capital LLC (TRC)](/funds/1533421.md) | 2026-06-30 | $4.4k | 3,922 | | Added +1,132 | ## Recent filings [All 1,039 filings](/companies/tpst/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-20 | 16:06 ET | [8-K](/filings/0001213900-26-111026.md) | 5.07 Shareholder vote results; 8.01 Other events | 0001213900-26-111026 | | 2026-10-19 | 16:05 ET | [8-K](/filings/0001213900-26-110669.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-26-110669 | | 2026-09-28 | 16:05 ET | [8-K](/filings/0001213900-26-104034.md) | 1.01 Entry into a material agreement; 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-26-104034 | | 2026-09-17 | 17:05 ET | [8-K](/filings/0001193125-26-394492.md) | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-394492 | | 2026-09-16 | 16:37 ET | [8-K](/filings/0001193125-26-393151.md) | 5.07 Shareholder vote results; 8.01 Other events | 0001193125-26-393151 | | 2026-09-15 | 16:06 ET | [8-K](/filings/0001193125-26-391903.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001193125-26-391903 | | 2026-08-24 | 16:43 ET | [8-K](/filings/0001193125-26-363695.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-363695 | | 2026-08-21 | 16:46 ET | [S-1](/filings/0001193125-26-361240.md) | Registration statement | 0001193125-26-361240 | | 2026-08-18 | 16:27 ET | [8-K](/filings/0001193125-26-355550.md) | 5.07 Shareholder vote results; 8.01 Other events | 0001193125-26-355550 | | 2026-08-13 | 16:37 ET | [10-Q](/filings/0001193125-26-349381.md) | Quarterly report, period 2026-06-30 | 0001193125-26-349381 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-130490.md), filed Mar 30, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1544227 - Tickers: TPST - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 26, 2026, 16:06 ET. No prices; not investment advice.